Troxerutin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Troxerutin
- DrugBank Accession Number
- DB13124
- Background
Troxerutin has been used in trials studying the treatment of Chronic Venous Insufficiency.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 742.6752
Monoisotopic: 742.232029162 - Chemical Formula
- C33H42O19
- Synonyms
- Troxerutin
- Troxerutina
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Capillary fragility •••••••••••• •••••• ••• Symptomatic treatment of Chronic venous insufficiency (cvi) •••••••••••• •••••• ••• Treatment of Chronic venous insufficiency (cvi) •••••••••••• •••••••• ••••••• ••• •••••••• Used in combination to treat Hemorrhoids Combination Product in combination with: Ginkgo biloba (DB01381), Heptaminol (DB13574) ••• ••• ••••••• Symptomatic treatment of Lymphoedema •••••••••••• •••••• ••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding can be increased when Abciximab is combined with Troxerutin. Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Troxerutin. Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Troxerutin is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Troxerutin. Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Troxerutin. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Elas gel Troxerutin (1500 mg/50g) + Ginkgo biloba (70 mg/50g) Lotion Topical Cho-A Pharm.Co.,Ltd. 2019-03-23 Not applicable US Elas gel Troxerutin (3000 mg/100g) + Ginkgo biloba (140 mg/100g) Lotion Topical Cho-A Pharm.Co.,Ltd. 2017-02-28 Not applicable US GINKOR FORT CAPSULE Troxerutin (300 mg) + Ginkgo biloba (14 mg) + Heptaminol hydrochloride (300 mg) Capsule Oral EP PLUS GROUP SDN. BHD. 2020-09-08 Not applicable Malaysia LACORYL® T SACHET Troxerutin (0.02 g) + Troxerutin (0.4 g) Powder, for solution Oral LABORATORIOS SYNTHESIS S.A.S. 2007-01-29 Not applicable Colombia LACORYL® T SACHET Troxerutin (0.02 g) + Troxerutin (0.4 g) Powder, for solution Oral LABORATORIOS SYNTHESIS S.A.S. 2007-01-29 Not applicable Colombia - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Elas gel Troxerutin (1500 mg/50g) + Ginkgo biloba (70 mg/50g) Lotion Topical Cho-A Pharm.Co.,Ltd. 2019-03-23 Not applicable US Elas gel Troxerutin (3000 mg/100g) + Ginkgo biloba (140 mg/100g) Lotion Topical Cho-A Pharm.Co.,Ltd. 2017-02-28 Not applicable US
Categories
- ATC Codes
- C05CA04 — Troxerutin
- C05CA — Bioflavonoids
- C05C — CAPILLARY STABILIZING AGENTS
- C05 — VASOPROTECTIVES
- C — CARDIOVASCULAR SYSTEM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as flavonoid-3-o-glycosides. These are phenolic compounds containing a flavonoid moiety which is O-glycosidically linked to carbohydrate moiety at the C3-position.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Flavonoids
- Sub Class
- Flavonoid glycosides
- Direct Parent
- Flavonoid-3-O-glycosides
- Alternative Parents
- 5-hydroxyflavonoids / Flavones / Chromones / Disaccharides / O-glycosyl compounds / Phenoxy compounds / Phenol ethers / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Alkyl aryl ethers show 11 more
- Substituents
- 1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 5-hydroxyflavonoid / Acetal / Alcohol / Alkyl aryl ether / Aromatic heteropolycyclic compound / Benzenoid / Benzopyran show 25 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7Y4N11PXO8
- CAS number
- 7085-55-4
- InChI Key
- IYVFNTXFRYQLRP-VVSTWUKXSA-N
- InChI
- InChI=1S/C33H42O19/c1-14-23(38)26(41)28(43)32(49-14)48-13-21-24(39)27(42)29(44)33(51-21)52-31-25(40)22-17(37)11-16(45-7-4-34)12-20(22)50-30(31)15-2-3-18(46-8-5-35)19(10-15)47-9-6-36/h2-3,10-12,14,21,23-24,26-29,32-39,41-44H,4-9,13H2,1H3/t14-,21+,23-,24+,26+,27-,28+,29+,32+,33-/m0/s1
- IUPAC Name
- 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4H-chromen-4-one
- SMILES
- C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(OCCO)=CC(O)=C4C3=O)C3=CC(OCCO)=C(OCCO)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0006083
- PubChem Compound
- 5486699
- PubChem Substance
- 347829247
- ChemSpider
- 4589027
- 38893
- ChEMBL
- CHEMBL3182320
- ZINC
- ZINC000085552699
- Wikipedia
- Troxerutin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Chronic Venous Insufficiency (CVI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Lotion Topical Injection, solution Intramuscular Tablet, coated Oral Capsule Oral Gel Topical Powder, for solution Oral Tablet Oral 300.000 mg Gel Topical 2 % Capsule Cream Solution / drops Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.43 mg/mL ALOGPS logP -0.55 ALOGPS logP -2.5 Chemaxon logS -2.7 ALOGPS pKa (Strongest Acidic) 7.14 Chemaxon pKa (Strongest Basic) -2.8 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 19 Chemaxon Hydrogen Donor Count 10 Chemaxon Polar Surface Area 293.21 Å2 Chemaxon Rotatable Bond Count 15 Chemaxon Refractivity 172.47 m3·mol-1 Chemaxon Polarizability 73.12 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 259.5999425 predictedDarkChem Lite v0.1.0 [M-H]- 260.3975425 predictedDarkChem Lite v0.1.0 [M-H]- 249.18747 predictedDeepCCS 1.0 (2019) [M+H]+ 258.3622425 predictedDarkChem Lite v0.1.0 [M+H]+ 262.8876425 predictedDarkChem Lite v0.1.0 [M+H]+ 251.47023 predictedDeepCCS 1.0 (2019) [M+Na]+ 259.9914425 predictedDarkChem Lite v0.1.0 [M+Na]+ 265.1234425 predictedDarkChem Lite v0.1.0 [M+Na]+ 257.41302 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 03:27 / Updated at February 21, 2021 18:54